human
plasmaderiv
protein
immunoglobulin
coagul
factor
fibrin
sealabstract
ant
albumin
wide
use
therapeut
mani
seriou
lifethreaten
medic
condit
human
origin
protein
ensur
excel
efficaci
compat
may
also
introduc
risk
unintent
diseas
transmiss
histor
virus
particularli
hepat
hiv
pose
seriou
threat
safeti
therapeut
fortun
molecular
biolog
major
virus
elucid
advanc
led
develop
implement
effect
donor
screen
test
mainli
base
immunoassay
nucleic
acid
test
result
signific
reduct
diseas
transmiss
risk
addit
viral
inactiv
remov
step
implement
valid
manufactur
reduc
risk
associ
known
well
unidentifi
virus
sinc
late
differ
class
transmiss
agent
refer
prion
identifi
new
risk
diseas
transmiss
howev
prion
diseas
rare
prion
transmiss
plasmaderiv
protein
report
date
prionrel
risk
minim
defer
donor
certain
key
risk
factor
manufactur
process
capabl
remov
prion
advanc
scienc
pathogen
safetyrel
technolog
complianc
good
manufactur
practic
manufactur
increasingli
stringent
regulatori
oversight
meant
plasmaderiv
protein
develop
today
highli
effect
therapeut
low
risk
diseas
transmiss
cohnoncley
fraction
process
anoth
bloodborn
hepat
viru
refer
develop
isol
therapeut
protein
human
plasma
nona
nonb
hepat
later
identifi
mainli
caus
base
solubl
differ
individu
protein
hepat
c
viru
hcv
becam
promin
given
solvent
condit
subsequ
techniqu
first
mani
hiv
infect
transmit
blood
filtrat
ultrafiltr
chromatographi
incorproduct
among
hemophil
patient
report
awarepor
manufactur
process
increas
puriti
yield
ness
potenti
viru
transmiss
blood
blood
product
product
advanc
led
continu
suppli
prompt
activ
research
develop
effort
field
human
plasmaderiv
protein
essenti
treatment
reduc
remov
inactiv
virus
well
emerg
mani
seriou
medic
condit
diseas
includ
albuvirus
min
shock
burn
treatment
immunoglobulin
immuon
riskreduct
measur
initi
question
nodefici
coagul
factor
hemophilia
antiidentifi
defer
diseasecarri
highrisk
donor
trypsin
hereditari
emphysema
although
human
plasmaderparticularli
import
diseas
associ
particuiv
protein
administ
save
million
live
everi
year
lar
behavior
geograph
region
diseasespecif
biolog
product
carri
risk
pathogen
contamin
diagnost
test
avail
regul
donor
qualifi
tabl
list
pathogen
shown
cation
well
establish
major
industri
countri
transmiss
potenti
transmiss
blood
continu
revis
accommod
emerg
diseas
histor
sinc
larg
pathogen
bacteria
parasit
sourceplasma
therapeut
industri
repres
remov
steril
filtrat
destroy
freezethaw
plasma
protein
therapeut
associ
ppta
also
implecycl
virus
pose
seriou
threat
safeti
ment
initi
improv
donor
select
process
one
plasmaderiv
protein
exampl
compil
nation
donor
deferr
registh
first
mani
bloodborn
virus
identifi
tri
nddr
databas
perman
defer
donor
north
hepat
b
viru
hbv
whose
surfac
antigen
discov
implement
hbv
test
america
avail
sinc
decemb
donor
select
first
layer
defenc
although
whole
blood
plasma
product
regul
transmiss
diseas
subsequ
collect
donat
mani
agenc
worldwid
often
test
major
clinic
relev
virus
tabl
posit
polici
profound
differ
way
whole
blood
elev
plasma
unit
remov
addit
remov
plasma
collect
store
process
unlik
blood
inactiv
step
incorpor
manufactur
process
process
collect
plasma
remov
cellular
compon
theretarget
pathogen
might
escap
detect
prevent
reduc
risk
contamin
cellassoci
pathotransmiss
emerg
virus
unknown
natur
test
gen
whole
blood
frozen
plasma
fractionaremov
inactiv
virus
measur
tion
store
subfreez
temperatur
longterm
storag
current
use
reduc
theoret
risk
prion
transof
frozen
plasma
allow
implement
hold
period
mission
discuss
detail
follow
section
donor
qualif
reassess
commonli
refer
donor
lookback
disqualifi
plasma
unit
remov
procedur
effect
lower
residu
risk
detect
bloodborn
viral
pathogen
may
associ
earli
infect
preserotradit
common
perspect
use
address
convers
window
period
marker
infect
pathogen
detect
issu
associ
whole
blood
plasundetect
specif
test
durat
window
period
defin
perform
mate
residu
risk
among
us
blood
donor
eg
probabl
specif
technolog
use
detect
serologythat
donor
donat
preseroconvers
window
base
test
ie
test
detect
viralspecif
antigen
antibosuggest
dramat
decreas
sinc
introduct
donor
hiv
die
window
period
could
result
limit
test
sensit
protocol
approxim
per
donor
viral
antigen
result
delay
antibodi
respons
per
donor
patient
improv
exist
technolog
develop
ment
new
one
test
base
nucleic
acid
technolog
screen
blood
plasma
donor
hcv
nat
increas
opportun
shorten
window
period
implement
follow
identif
viru
depend
target
viral
infect
acut
viremia
may
respons
major
case
nona
nonb
viral
assess
detect
viral
antigen
nucleic
acid
hepat
develop
analytespecif
reagent
base
whole
blood
plasma
sampl
wherea
resolv
infect
viral
antigen
firstgener
test
base
chronic
viremia
readili
indic
presenc
singl
peptid
subsequ
improv
introduc
antibodi
two
test
util
multipl
peptid
antibodi
captur
approv
analys
differ
version
test
compar
indic
increment
modif
improv
assay
perform
preseroconvers
window
detect
antibodi
respons
viral
infect
refor
hcv
rel
long
averag
approxim
day
main
one
convent
wide
use
approach
infect
donor
typic
unawar
infect
determin
preval
relev
human
pathogen
within
symptom
evid
period
despit
fluctuat
specif
popul
detect
antibodi
diagnost
viral
load
sometim
exceed
copi
viral
genom
indic
remain
import
tool
particularli
face
ml
condit
contribut
elev
residu
risk
newli
emerg
pathogen
whose
characterist
poorli
deper
us
volunt
blood
donor
associ
prefin
unknown
moreov
detect
differ
class
seroconvers
window
virusspecif
antibodi
offer
predict
valu
addit
diagnost
valu
appli
donor
patient
histori
viru
specif
antibodi
test
remain
import
compon
current
donor
screen
program
target
sever
human
pathovir
antigen
detect
earli
infect
appeargen
hcv
typic
establish
anc
circul
antibodi
period
frequent
overlap
debilit
chronic
infect
accuraci
diagnosi
prodrom
mani
donor
like
appear
asymptomat
type
infect
critic
antibodi
test
protocol
viral
replic
particularli
robust
period
typic
involv
combin
donor
screen
confirmavir
load
typic
increas
exponenti
rel
tori
assay
short
period
time
understand
phase
infect
may
pose
greatest
level
risk
public
health
product
safeti
direct
detect
specif
viral
antigen
provid
sinc
sever
enzym
immunoassaybas
method
opportun
notifi
infect
donor
remov
potenti
approv
primari
donor
screen
test
detect
infecti
plasma
prior
entri
manufactur
inventori
hivspecif
antibodi
three
addit
test
system
clude
western
blot
analysi
indirect
immunofluoresc
approv
confirmatori
test
infect
convent
paradigm
routin
detect
activ
character
acut
primari
phase
patient
viremia
human
blood
plasma
establish
approximateexhibit
wide
rang
flulik
symptom
ly
year
ago
implement
radioimmun
assay
period
seroconvers
typic
follow
period
mark
ria
specif
hbv
surfac
antigen
hbsag
end
preseroconvers
window
howev
incub
initi
refer
australia
au
antigen
time
may
vari
wide
day
month
hepatitisassoci
antigen
associ
viral
seroconvers
may
occur
week
longmark
transmiss
infecti
hepat
plasterm
asymptomat
phase
characterist
latent
lowmabas
therapi
gener
interest
infecti
viral
level
persist
infect
typic
follow
seroconvers
estiparticl
partit
plasma
fraction
process
abil
analyz
partit
pathogen
trackindustri
regulatori
goal
recent
licensur
number
ing
defin
marker
creat
new
opportun
design
fracnat
test
system
specif
detect
rna
tionat
purif
process
pathogen
safeti
provid
opportun
elimin
test
primari
consider
moreov
systemat
detect
donor
hiv
screen
protocol
hbsag
provid
foundat
develop
screen
qualiti
control
strategi
design
improv
qualiti
detect
viral
nucleic
acid
plasma
prior
product
deriv
nat
offer
sensit
flexibl
platform
detect
detect
hbsag
use
specif
monoclon
viremia
blood
plasma
donor
creat
addit
polyclon
antibodi
firmli
establish
histori
transfuopportun
remov
plasma
unit
contamin
clinic
sion
medicin
plasma
industri
practic
high
level
empti
relev
pathogen
hbv
hcv
hiv
defer
viru
particl
addit
high
titer
intact
infecti
viru
infect
donor
experi
demonstr
particl
mean
detect
surfac
antigen
gener
efficaci
nat
test
potenti
supplant
viral
antigen
effect
measur
interdict
donat
donor
test
direct
indic
viremia
allow
elimin
acut
phase
infect
initi
effort
develop
less
effect
redund
test
nat
test
also
emerg
implement
screen
test
involv
multipl
technolog
platan
import
technolog
detect
less
sever
viral
form
howev
could
satisfi
oper
requirepathogen
parvoviru
hepat
viru
hav
ment
associ
screen
whole
blood
plasma
infect
pathogen
gener
selflimit
unit
assay
reli
solidphas
immunochemistri
effect
immun
respons
use
nat
test
detect
hbsag
ria
elisa
gain
earli
identifi
virem
donat
remov
ensur
convalesfavor
tradit
assay
includ
complement
fixac
donor
whose
plasma
may
contain
protect
virusspecif
tion
counterimmunodiffus
method
current
sever
antibodi
retain
nat
also
play
increasingli
imtest
system
differ
manufactur
licens
us
portant
role
resolv
issu
particular
emerg
pathogen
fda
use
donor
screen
confirmatori
test
time
develop
implement
test
approv
sensit
test
system
pend
although
critic
incid
hbv
infect
vari
significantli
worldwid
repres
studi
us
volunt
blood
donor
indic
nucleic
acid
sever
properti
make
effect
target
detect
abil
dna
rna
hybrid
draw
screen
paradigm
alreadi
establish
complementari
molecul
mean
great
deal
control
hbv
earli
emphasi
place
develop
assay
exert
assay
specif
target
nucleic
acid
direct
detect
public
polit
pressur
sequenc
known
nat
method
typic
combin
nucleic
heighten
sens
urgenc
close
infecti
window
acid
hybrid
amplif
technolog
driven
either
beyond
achiev
implement
enzymat
chemic
achiev
highli
sensit
detect
antihiv
antibodi
screen
howev
ambigu
surroundof
specif
nucleic
acid
pcr
earliest
ing
outcom
sever
larg
clinic
studi
instil
sens
wide
recogn
method
appli
detect
uncertainti
potenti
benefit
associ
quantiti
viral
nucleic
acid
howev
tigen
screen
despit
doubt
util
method
offer
altern
technolog
platform
similar
test
field
fda
adopt
formanc
specif
amplif
nucleic
acid
screen
interim
measur
facilit
expand
donor
target
system
includ
transcript
mediat
amplificahiv
screen
protocol
howev
region
regulatori
tion
tma
nucleic
acid
sequenc
base
amplif
nasag
notabl
associ
europ
japan
ba
thermophil
stranddisplac
amplif
declin
adopt
protocol
safeti
benefit
associ
tsda
ligas
chain
reaction
lcr
branch
dna
ate
implement
expand
protocol
assay
bdna
coupl
effici
nucleic
acid
isolagener
perceiv
margin
replac
method
technolog
could
provid
foundatigen
test
effect
screen
technolog
tion
highli
effici
highthroughput
test
platform
nat
method
also
provid
opportun
introduc
economi
peutic
industri
appli
nat
test
hcv
pool
highthroughput
test
environ
increas
sensiplasma
sampl
compli
european
us
initi
tiviti
associ
nat
method
allow
test
nat
test
also
implement
improv
interdicpool
sampl
individu
sampl
need
test
tion
remov
hiv
hbv
havsuspect
posit
target
pathogen
vast
macontamin
unit
plasma
inventori
manufactur
joriti
sampl
neg
pool
strategi
greatli
enhanc
stream
nat
method
enhanc
margin
safeti
oper
effici
reduc
number
test
sampl
blood
plasma
product
allow
detect
viral
thu
effect
increas
throughput
util
fluorespathogen
earlier
window
period
achiev
use
cent
chemiluminesc
detect
chemistri
nat
methcurr
antigen
antibodi
test
exampl
window
od
facilit
process
consolid
reduc
assay
time
addiperiod
associ
antibodi
assay
approxim
tional
probespecif
detect
target
differenti
day
assay
reduc
window
tate
multiplex
assay
therebi
increas
array
period
day
applic
nat
assay
target
reduc
number
test
perform
final
rna
reduc
window
period
progress
introduct
autom
gradual
reduc
day
depend
pool
strategi
employ
us
number
laborintens
step
decreas
time
implement
licens
nat
assay
allow
requir
perform
assay
reduct
test
redund
discontinu
test
howev
mani
develop
countri
sinc
activ
dialog
underway
among
scienimplement
nat
techniqu
hinder
complex
tist
blood
plasma
industri
molecular
diagnost
high
cost
develop
regulatori
agenc
worldwid
concern
introduct
nat
method
protocol
establish
test
implement
new
test
platform
upgrad
bloodborn
viral
pathogen
semiannu
meet
internaof
older
one
consist
strong
emphasi
continut
collabor
help
establish
standard
uniou
improv
biolog
product
industri
form
polici
collabor
develop
internacommit
past
decad
test
procedur
tional
standard
nat
method
tabl
ii
provid
basi
complement
viral
remov
inactiv
measur
design
variou
region
regulatori
polici
industri
initi
productspecif
manufactur
stream
provid
better
safeth
applic
intern
unit
descript
empir
featur
plasmaderiv
therapeut
protein
calli
deriv
consensusbas
potenc
rather
put
remov
inactiv
virus
physic
entiti
enabl
creation
perform
standard
across
multipl
technolog
platform
legisl
guidanc
document
frequent
specifi
perform
standard
variou
viral
valid
studi
region
world
earli
plasma
industri
initi
viral
inactiv
studi
eu
committe
proprith
eu
codif
specif
detect
etari
medicin
product
cpmp
requir
manufactur
pathogen
viral
nucleic
acid
pool
human
plasma
open
blood
plasma
product
implement
viral
inactivationremovth
door
new
era
detect
viral
pathogen
plasma
al
step
process
accord
regulatori
requireus
manufactur
protein
therapeut
plasma
therament
viral
valid
studi
perform
estim
davi
et
al
hbv
hbv
dna
saldanha
et
al
hcv
hcv
rna
saldanha
et
al
saldanha
et
al
hav
hav
rna
saldanha
et
al
level
viru
reduct
across
manufactur
process
regulatori
author
recommend
incorpor
least
two
effecthes
studi
known
amount
viru
deliber
ad
tive
step
unrel
clearanc
mechan
manufac
spike
product
intermedi
materi
treattur
process
least
one
step
effect
ed
accord
manufactur
specif
use
benchscal
nonenvelop
virus
model
product
process
viru
reduct
calcul
ideal
pathogen
viru
directli
test
detercompar
level
viru
infect
remain
end
mine
viral
clearanc
valu
howev
clinic
releprocess
level
start
materi
sinc
manuv
virus
propag
easili
vitro
result
specif
factur
process
consist
multipl
step
challeng
sysmodel
virus
similar
physicochem
characterist
tem
viru
begin
process
sampl
final
use
repres
relev
uncultiv
virus
addit
product
practic
strategi
would
requir
massiv
nonspecif
model
virus
differ
physicochem
characamount
viru
someth
difficult
obtain
result
terist
includ
evalu
theoret
capabl
individu
step
process
usual
evalu
break
manufactur
process
clear
unknown
undetect
virus
process
individu
step
technic
thu
singl
indic
viru
use
assur
viral
clearanc
reason
also
allow
accur
character
capac
manufactur
process
known
unknown
condit
critic
viral
reduct
better
understandvirus
instead
test
panel
relev
model
virus
use
ing
mechan
viral
clearanc
valid
studi
determin
capac
viral
reduct
manufactur
process
tabl
iii
short
list
common
model
viru
reduct
express
logarithm
scale
overal
test
virus
use
viral
valid
studi
mimic
viru
reduct
capac
process
defin
sum
bloodborn
virus
potenti
caus
clinic
infect
log
reduct
factor
individu
step
howev
simpl
summat
individu
reduct
factor
use
measur
viral
safeti
individu
clearanc
step
yield
consid
neglig
includ
overal
clearanc
process
ad
numer
reduct
viru
infect
achiev
routin
step
low
individu
reduct
factor
ad
step
process
purif
oper
dedic
viru
reducshar
mechan
viru
clearanc
may
overestim
tion
step
depend
method
clearanc
strategi
viru
reduct
capac
process
effect
step
one
classifi
remov
physic
separ
inactiv
irrethat
clear
least
unit
viru
ie
versibl
loss
viral
infect
viru
remov
often
achiev
reduct
titer
robust
step
one
clear
viru
partit
virus
protein
interest
precipitaregardless
variabl
product
paramet
gener
tion
chromatographi
filtrat
emphas
singl
effect
robust
step
provid
assur
viral
assur
effect
viru
reduct
remov
step
process
safeti
sever
step
overal
log
reduct
condit
need
care
defin
control
carri
complianc
good
manufactur
practic
gmp
regulaeffect
virus
hcv
transmit
tion
immunoglobulin
manufactur
process
reli
entir
fraction
remov
viru
consequ
addit
viral
inactivationremov
step
differ
mechan
cohnoncley
fraction
well
establish
effici
action
requir
manufactur
process
assur
viral
method
allow
multipl
stepwis
extract
therapeut
safeti
protein
figur
frozen
plasma
thaw
slowli
centrifug
remov
cryoprecipit
cold
insol
ubl
plasma
fraction
contain
fibrinogen
factor
viii
fviii
capryl
octano
acid
use
precipit
von
willebrand
vwb
factor
solubl
differ
remov
lipidslipoprotein
purif
process
protein
fraction
remain
supernat
effluent
intraven
immunoglobulin
ivig
acid
condimanipul
ad
differ
amount
alcohol
ethanol
tion
treatment
also
inactivatesremov
least
chang
temperatur
ph
andor
ionic
strength
condit
envelop
virus
coupl
depth
filtrat
alcohol
precipit
fraction
differ
protein
nonenvelop
virus
also
remov
separ
partit
centrifug
filtrat
although
design
specif
viru
remov
protein
usual
solubl
water
solut
fraction
process
possess
vari
capac
clear
hydrophil
amino
acid
interact
water
molecul
polyethylvirus
viral
valid
studi
help
explain
fviii
concenen
glycol
peg
inert
nondenatur
watersolubl
polytr
produc
implement
viral
inactiv
mer
precipit
protein
virus
aqueou
solut
measur
becam
contamin
multipl
virus
exclud
protein
interact
water
exampl
immunoglobulin
produc
period
never
transpeg
precipit
step
capabl
remov
virus
mit
hiv
earli
fviii
concentr
deriv
purif
process
cryoprecipit
viral
valid
studi
show
viral
clear
anc
across
initi
precipit
step
gener
cryoprecipit
contrast
immunoglobulin
deriv
fracalthough
tradit
purif
scheme
reli
exclus
tion
iiiii
undergo
addit
precipit
step
fraction
iii
alcohol
precipit
mani
newli
develop
process
fviii
purifi
product
also
remov
immun
globulin
use
chromatographi
step
remov
conmodel
nonenvelop
model
envelop
tamin
includ
virus
howev
complex
virus
must
emphas
fraction
step
biolog
process
stream
chromatographi
typic
use
primari
extract
often
employ
downbiolog
immunolog
reaction
induc
nanofilstream
polish
step
partial
purifi
fraction
chromatotr
theori
limit
pore
size
smaller
graphic
method
separ
protein
base
differ
pore
smaller
virus
retain
howev
sizebas
physicochem
characterist
sinc
virus
consist
mani
exclus
appli
plasma
protein
well
virus
differ
protein
may
separ
mani
differ
kind
current
smallest
plasma
product
pass
easili
chromatograph
method
filter
nanofiltr
technolog
improv
reason
expect
avail
membran
capabl
separ
virus
affin
chromatographi
use
biolog
ligand
antiboa
small
parvoviru
protein
larg
igg
fviii
die
cofactor
recogn
bind
complementari
protein
exampl
one
purif
process
fviii
immobil
monoclon
antibodi
specif
captur
fviii
allow
contamin
protein
porcin
parvoviru
inactiv
method
render
virus
noninfecti
physic
ppv
log
polioviru
small
nonenvelop
virus
chemic
mean
may
advers
affect
pass
protein
product
exampl
advers
effect
includ
protein
denaionexchang
chromatographi
use
differ
charg
turat
loss
biolog
activ
alter
antigen
separ
protein
although
bind
characterist
protein
product
neoantigen
induct
antibodi
inhibitor
chromatograph
process
well
understood
viru
bindin
recipi
stabil
usual
ad
protect
biolog
ing
consequ
mani
ligand
use
viral
activ
reduc
protein
aggreg
ad
stabil
clearanc
rel
gener
bind
properti
involv
inactiv
chemic
must
remov
product
combin
ionic
hydrophob
hydrogen
bond
van
der
subsequ
manufactur
step
remov
reduc
level
waal
interact
one
new
ivig
purif
process
result
recoveri
loss
extend
process
time
chromatographi
step
separ
impur
igg
commonli
use
chemic
inactiv
step
treatment
also
clear
bovin
viral
diarrhea
viru
bvdv
surrowith
solventdeterg
low
ph
aceton
use
gate
hcv
ppv
model
human
parvoviru
albumin
process
capryl
use
inactiv
enremov
hiv
pseudorabi
viru
prv
model
human
herp
velop
virus
immun
globulin
solut
licens
method
virus
reoviru
hav
detect
physic
inactiv
virus
also
includ
pasteur
heatdepth
filter
origin
develop
plasma
fraction
solut
vapor
heat
termin
dri
heat
ation
industri
replac
asbesto
prefilt
clarifi
filter
basic
consist
diatomac
earth
cellulos
polymer
bind
resin
bind
resin
also
confer
posit
charg
solventdeterg
sd
treatment
disrupt
lipid
coat
matrix
enabl
filter
function
ion
exchang
envelop
virus
consist
gentli
stir
plasma
protein
chromatograph
medium
depth
filtrat
effect
remov
solut
nonvolatil
organ
solvent
trinbutylphosph
envelop
nonenvelop
virus
product
ivig
tnbp
deterg
tween
triton
sodium
albumin
antitrypsin
cholat
sd
treatment
first
licens
fda
consid
breakthrough
viral
safeti
simpliciunlik
chromatographi
step
develop
protein
ty
effect
inactiv
envelop
virus
mainpurif
viru
remov
coincident
viru
retain
high
protein
recoveri
hiv
bvdv
prv
tentiv
filter
nanofilt
develop
specif
reinactiv
detect
sd
treatment
fviii
move
virus
virus
larger
pore
size
nanofilt
ivig
process
intermedi
downstream
process
requir
retain
combin
size
exclus
adsorpt
mechato
remov
sd
agent
often
exist
step
remov
nism
smaller
less
rigid
plasma
protein
pass
protein
contamin
main
limit
failur
inactinanofiltr
perform
rel
mild
physiolog
vate
nonenvelop
virus
hiv
hcv
condit
pressur
ph
osmolar
temperatur
hbv
transmiss
sdtreat
plasma
product
sinc
requir
stabil
chemic
agent
result
introduct
sever
case
hav
parvoviru
biolog
integr
product
compromis
advers
transmiss
sdtreat
clot
factor
concentr
result
indic
model
viru
ppv
resist
addit
capac
induc
precipit
section
heat
treatment
parvoviru
suggest
capryl
also
inactiv
virus
propos
mecha
pasteur
inactiv
envelop
nonenn
inactiv
lipophil
nonion
capryl
disvelop
virus
albumin
howev
pasteur
presrupt
viral
lipid
membran
render
viru
noninfec
sucros
less
effect
nonenvelop
virus
tiou
capryl
inactiv
studi
one
new
ivig
process
reoviru
reduct
similarli
recent
report
show
hiv
bvdv
prv
complet
inactiv
parvoviru
transmiss
pasteur
immunoglobulin
exposur
minut
variat
incub
time
presenc
stabil
indic
heat
solut
may
temperatur
ph
protein
concentr
capryl
concentranot
effect
elimin
high
concentr
nonent
within
manufactur
specif
affect
viru
inacvelop
virus
parvoviru
tivat
demonstr
potenti
capryl
treatment
use
robust
altern
sd
treatment
pressur
steam
vapor
heat
use
treat
coagu
lation
concentr
twostag
vapor
heat
involv
hour
although
commonli
use
manufactur
process
mbar
follow
hour
wash
albumin
past
aceton
shown
mbar
inactiv
hiv
tickborn
inactiv
hiv
bvdv
enceph
viru
prv
equin
prv
rhinopneumon
viru
model
hav
vapor
heat
inactiv
envelop
virus
gener
nonen
velop
virus
includ
hav
treatment
may
inactisimilar
fortuit
util
alcohol
precipit
vate
parvoviru
complet
viru
remov
step
low
ph
incub
serv
two
function
incub
ivig
low
ph
ph
initi
develop
reduc
anticomplementari
activ
avoid
aggreg
perdur
termin
dri
heat
treatment
final
contain
freez
mit
intraven
infus
howev
incub
ivig
low
ph
dri
product
heat
temperatur
rang
also
inactiv
substanti
amount
envelop
virus
vari
length
time
termin
low
ph
final
incub
step
one
ivig
purif
process
dri
heat
treatment
develop
inactiv
hiv
coagulahiv
bvdv
prv
inactiv
detect
tion
factor
concentr
involv
heat
day
respect
howev
later
studi
show
inactiv
envelop
virus
hbv
hcv
requir
stringent
condit
result
fviii
product
treat
pasteur
heat
aqueou
stabil
protein
solubi
dri
heat
even
higher
temperatur
eg
tion
develop
world
war
ii
albumin
longer
period
time
eg
hour
treatment
inactiv
ship
world
treat
case
shock
case
signific
level
envelop
nonenvelop
virus
hiv
hbv
hcv
ever
trace
transfus
effect
step
depend
residu
cake
pasteur
albumin
pasteur
final
contain
moistur
formul
approv
pharmacopei
method
viral
inactiv
albumin
prepar
result
viral
valid
studi
support
virucid
capac
albumin
pasteur
extend
effect
experi
hepat
virus
hiv
led
nonenvelop
virus
pasteur
albumin
final
implement
mani
viral
remov
inactiv
technolocontain
inactiv
envelop
virus
hiv
bvdv
prv
gie
plasma
fraction
industri
current
nonenvelop
virus
reoviru
hav
near
magic
bullet
inactiv
virus
process
detect
contrast
ppv
reduct
techniqu
anticip
near
futur
thu
new
producachiev
heat
hour
blumel
et
tion
process
design
contain
orthogon
reduct
step
al
confirm
resist
ppv
albumin
pasteurizato
assur
broad
effect
viru
reduct
within
specif
prodtion
also
report
parvoviru
unlik
model
uct
stream
tabl
iv
summar
viral
reduct
across
sever
anim
viru
inactiv
heat
minut
repres
manufactur
process
overal
global
reduc
tabl
iv
reduct
envelop
nonenvelop
virus
across
manufactur
process
process
tion
across
manufactur
process
calcul
ad
signific
reduct
observ
tabl
iv
nonenvelop
reduct
factor
individu
step
viru
reduct
achiev
combin
remov
step
valu
collect
result
method
describ
precipit
filtrat
nanofiltr
inactiv
previou
section
step
pasteur
dri
heat
treatment
group
virus
often
lead
less
sever
clinic
outcom
eu
envelop
virus
eu
regulatori
agenc
recomregulatori
agenc
requir
least
one
effect
mend
manufactur
process
contain
least
two
effect
reduct
step
mechanist
independ
step
clearanc
capac
step
includ
chemic
physic
presenc
multipl
step
capabl
remov
treatment
precipit
filtrat
integr
inactiv
inactiv
wide
varieti
virus
complet
differ
remov
envelop
virus
shown
tabl
iv
capac
mechan
provid
greatest
assur
viru
survivmanufactur
process
inactivateremov
envelop
virus
ing
one
step
clear
anoth
step
howev
viral
hiv
hcv
hbv
high
inactiv
remov
step
use
implement
properli
product
carri
adher
clearanc
nonenvelop
virus
parvoviru
hav
difficult
across
manufactur
process
still
current
gmp
cgmp
manufactur
plasma
product
made
major
invest
improv
element
critic
latenc
period
small
number
case
howev
product
integr
viral
safeti
facil
equip
two
case
presumpt
vcjd
transmiss
design
qualif
valid
process
control
monitorus
pack
red
blood
cell
report
uk
ing
qualiti
assur
standard
oper
procedur
staff
therefor
vcjd
transmiss
blood
possibl
although
train
increasingli
rigor
regulatori
inspect
rare
past
decad
also
play
key
role
promot
enforc
conclus
posit
result
mani
earli
atcgmp
complianc
industri
tempt
transfer
cjd
anim
blood
howev
rel
recent
sheep
model
studi
convincingli
demon
strate
transmiss
tse
whole
blood
transfus
blood
sampl
collect
preclin
stage
indicatprion
diseas
transmiss
spongiform
encephalopathi
ing
asymptomat
anim
carri
infecti
tse
group
fatal
neurodegen
disord
link
agent
use
intracerebr
inocul
infect
misfold
prion
protein
notabl
tse
includ
also
detect
blood
sampl
rodent
tse
modscrapi
sheep
bovin
spongiform
encephalopathi
bse
el
mad
cow
diseas
cattl
creutzfeldtjakob
diseas
cjd
human
diseas
featur
long
latenc
period
rang
year
decad
accumul
pathogen
obviou
solut
manag
cjdrelat
risk
prion
protein
scrapi
form
prp
sc
mainli
cn
implement
screen
assay
capabl
detect
marker
follow
epidem
bse
uk
new
ill
preclin
stage
us
alon
estim
form
cjd
appear
mainli
uk
distinct
clinic
blood
donor
defer
theoret
patholog
featur
includ
appear
prp
sc
risk
vcjd
transmiss
sinc
vcjd
virtual
nonexislymphoid
tissu
describ
classic
cjd
tent
us
donor
loss
could
avoid
accur
case
new
ill
name
variant
cjd
vcjd
screen
test
avail
distinguish
cjd
epidemiolog
experiment
howev
pathogen
prion
protein
far
evad
detecevid
strongli
suggest
causal
link
bse
vcjd
tion
blood
sampl
practic
antemortem
screen
test
possibl
due
consumpt
bsecontamin
meat
prodfor
pathogen
current
avail
hand
uct
grow
practic
use
postmortem
test
exclud
infectth
emerg
vcjd
along
possibl
oral
rout
ed
beef
human
consumpt
reduc
risk
transmit
transmiss
peripher
lymphoid
tissu
involv
bse
human
popul
thu
indirectli
improv
safeti
prompt
concern
vcjd
may
pose
higher
risk
level
blood
blood
product
classic
cjd
term
transmiss
blood
blood
product
therefor
import
examin
risk
base
absenc
reliabl
antemortem
vitro
diagnost
test
epidemiolog
experiment
evid
cjd
deferr
polici
way
exclud
highrisk
donor
donor
famili
histori
cjd
patient
blood
infect
test
donor
deferr
undergon
certain
medic
procedur
associ
transmiss
cjd
dura
mater
transplant
human
pituitaryderiv
growth
hormon
administr
exclud
epidemiolog
point
view
classic
cjd
decis
also
made
stop
process
uk
plasma
transmit
blood
blood
product
case
deriv
long
period
time
would
expect
among
frequent
blood
blood
product
recipi
patient
hemophilia
thalasa
major
challeng
defer
donor
elev
semia
sickl
cell
diseas
howev
rate
classic
cjd
risk
expos
bse
agent
balanc
occurr
elev
popul
retrospectheoret
risk
cjd
transmiss
need
stabl
tive
studi
also
conduct
transfus
recipi
blood
suppli
regulatori
agenc
around
world
recomfrom
donor
later
develop
classic
cjd
classimend
geograph
deferr
polici
polici
mainli
excal
cjd
transmiss
detect
vcjd
epidemioloclud
donor
spent
certain
amount
time
uk
gy
data
remain
limit
diseas
short
histori
long
bse
epidem
period
begin
end
us
stringent
criteria
exclud
ty
correl
clearanc
prp
re
donor
stay
uk
cumul
month
infect
plasma
purif
process
demonstratfr
cumul
year
militari
base
europ
ed
prion
confirmationdepend
immunoassay
also
cumul
month
risk
period
us
polici
also
develop
use
benchscal
clearanc
studi
exclud
donor
blood
transfus
receiv
bovin
insulin
prepar
uk
present
australia
separ
prion
protein
entiti
may
accomjapan
defer
donor
spent
month
uk
plish
exploit
prion
structur
solutionst
polici
like
revis
properti
prion
hydrophob
aggreg
form
mechan
cjd
transmiss
becom
better
understood
prion
protein
often
associ
cellular
compon
membran
aggreg
vari
size
nanomet
micron
depend
sourc
prepar
tissu
desir
therapeut
protein
small
compar
prion
particl
sediment
filtrat
use
prion
agent
robust
treatment
heat
remov
prion
impur
use
well
defin
solut
condit
solvent
deterg
ioniz
radiat
inactiv
virus
ph
organ
agent
temperatur
promot
aggregacannot
reli
upon
elimin
tse
infect
tse
tionprecipit
prion
remov
use
sediinactiv
achiev
use
extrem
method
mentat
filtrat
tabl
v
time
degre
prion
treatment
caustic
autoclav
method
also
clearanc
reliabl
predict
basi
condidestroy
biolog
product
interest
therefor
remov
tion
use
purifi
protein
thu
prudent
practic
prion
agent
viabl
mean
reduc
theoret
evalu
remov
prion
agent
casebycas
basi
risk
associ
transmiss
tse
plasmaand
reli
analog
deriv
protein
one
best
studi
process
prion
clearanc
determin
capac
prion
remov
manufactur
cohnoncley
fraction
gener
methodolog
proprocess
prion
clearanc
studi
perform
studi
cess
see
section
lower
temperatur
plasma
analog
viral
clearanc
studi
benchscal
model
increas
alcohol
concentr
make
ph
adjust
manufactur
process
use
section
tse
spike
select
precipit
class
protein
number
laboratoar
typic
deriv
infect
brain
homogen
rie
investig
inher
abil
cohnoncley
high
titer
prion
protein
infect
also
see
section
process
remov
spike
prion
protein
ty
cryosepar
fraction
separ
yield
partit
tse
infect
purif
profactor
viiivwb
fibrinogenfactor
ix
respect
figur
cess
monitor
rodent
bioassay
although
sensit
two
plasma
intermedi
highest
protein
assay
typic
requir
number
month
complet
concentr
clearanc
spike
prion
altern
sensit
western
blot
assay
develop
follow
fraction
separ
fraction
iiiii
separaand
use
monitor
partit
proteinas
resist
tion
first
signific
prion
remov
step
effect
form
prion
prp
re
surrog
marker
tse
volumevolum
alcohol
combin
low
temperatur
centrifug
result
remov
prp
sc
hamster
prp
sc
strain
deriv
sheep
scrapi
respect
effluent
suggest
prion
precipii
use
clearanc
studi
howev
import
establish
tate
aggreg
use
specif
solutionst
condit
hamster
scrapi
valid
model
partit
human
fraction
iiiii
clearanc
clearli
benefici
downstream
prion
compar
studi
partit
human
sheep
product
plasma
protein
fraction
albumin
hamster
form
prp
sc
conduct
three
plasma
cohnoncley
process
howev
remov
favor
purif
step
chosen
demonstr
low
cryoseparath
immunoglobulin
product
prion
spike
copurifi
tion
intermedi
peg
precipit
fraction
iiiii
past
start
materi
ivig
high
peg
precipit
clearanc
process
fortun
step
immunoglobulin
puriprp
sc
hamster
scrapi
spike
model
brief
found
ficat
significantli
clear
spike
prion
immuthat
prp
sc
deriv
vcjd
classic
cjd
sporad
cjd
noglobulin
product
exampl
fraction
iii
separ
reli
gerstmann
sheinker
diseas
human
brain
tissu
partion
solut
condit
maintain
solubl
igg
tion
quantit
similarli
prp
sc
deriv
sheep
alcohol
low
temperatur
precipit
prion
hamster
scrapi
data
indic
case
bioar
remov
use
centrifug
sediment
chemic
separ
hamster
scrapi
use
predict
partit
human
speci
prion
factor
control
precipit
prp
sc
cohn
prepar
spike
materi
relat
issu
oncley
fraction
investig
detail
physic
properti
circul
tse
infect
blood
sever
factor
identifi
control
precipit
measur
brain
homogen
may
may
prp
sc
solut
among
ph
alcohol
content
salt
ideal
model
endogen
circul
tse
infect
concentr
paramet
total
protein
concentramicrosom
highli
purifi
prepar
brain
homoget
specif
protein
constitu
temperatur
found
nate
propos
investig
altern
less
import
term
precipit
prp
sc
crude
brain
homogen
rule
membranebound
form
new
ivig
product
develop
use
chromatoth
tse
infect
prion
protein
ie
crude
clarifi
graphic
process
major
purif
method
promicrosom
fraction
brain
homogen
result
lowest
cess
prion
effect
precipit
low
ph
presenc
remov
measur
spike
studi
highli
purifi
form
capryl
remov
subsequ
filtrat
step
signifia
fibril
full
length
scrapi
protein
tend
result
high
cant
prion
reduct
factor
valid
level
remov
thu
use
less
purifi
fraction
repres
step
process
organ
agent
peg
also
conserv
estim
prion
remov
use
effect
remov
spike
prion
process
intermedi
one
purif
process
addit
peg
yield
prp
sc
remov
conclus
util
precipit
coupl
sediment
filtrat
effect
mean
remov
prion
reduc
past
decad
overal
risk
acquir
seriou
risk
tse
transmiss
nanofiltr
size
exclusionbas
viral
diseas
plasmaderiv
protein
reduc
method
also
demonstr
signific
potenti
significantli
fact
confirm
transmiss
hbv
hcv
remov
prion
exampl
viresolv
nfp
hiv
us
licens
viral
reduc
plasma
deriv
normal
flow
parvoviru
viresolv
membran
millireport
recent
year
favor
statu
result
pore
billerica
usa
yield
remov
variou
prepar
combin
measur
includ
screen
defer
prion
spike
model
process
solut
similar
highrisk
donor
test
collect
donat
use
immuremov
valu
measur
use
novasip
pall
corp
noassay
nat
incorpor
valid
viru
east
hill
ny
usa
planova
asahi
kasei
pharma
remov
inactiv
step
product
process
tokyo
japan
nanofilt
chromatographi
method
may
also
establish
increasingli
stringent
pathogen
safeti
regulab
effect
remov
prion
variou
degre
tion
spite
advanc
risk
pathogen
transmiss
plasma
product
never
assum
nonexist
issu
relat
investig
prion
remov
use
current
unknown
virus
could
emerg
known
virus
could
spike
materi
deriv
rodent
brain
tissu
typic
redistribut
geograph
mutat
new
strain
devel
tabl
iv
therefor
predict
